RCEL Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Revenue: Approximately $19.3 million, reflecting a 4% increase year-over-year and a 10% increase sequentially from Q4 2025. This marks the highest quarterly revenue in the last year.
Gross Margin: 81.7%, down from 84.7% in the prior year, primarily due to inventory reserves and a shift in product mix.
Operating Expenses: $24.5 million, an 11% decrease year-over-year, attributed to cost-saving measures implemented in 2025.
Net Loss: $10.6 million or $0.35 per share, an improvement from a loss of $13.9 million or $0.53 per share in the prior year.
Cash Position: Ended the quarter with approximately $14.3 million in cash and marketable securities, with net cash used of about $9.9 million.

2. Strategic Updates and Business Highlights

Leadership Changes: Cary Vance was confirmed as President and CEO, emphasizing a focus on stabilizing the business and improving operations.
Product Performance: RECELL continues to be a key driver of revenue, with improved utilization patterns as reimbursement dynamics normalize. Cohealyx is seeing early adoption with positive clinical data from the Cohealyx-I study.
New Agreements: A long-term agreement with BARDA was announced to support U.S. burn emergency preparedness, providing a modest recurring revenue stream.
Market Engagement: Increased clinical engagement was noted at the American Burn Association Annual Meeting, highlighting the integration of products into clinical workflows.

3. Forward Guidance and Outlook

Full-Year Revenue Guidance: Reaffirmed guidance of $80 million to $85 million for 2026, with expectations for continued sequential growth driven by increased utilization across core accounts.
Q2 Expectations: Anticipated continued growth based on the momentum from Q1, with a focus on demonstrating repeatable progress.

4. Challenges and Points of Concern

Market Dynamics: The business is still influenced by previous ordering patterns, with a shift away from bulk purchasing impacting year-over-year comparisons.
Gross Margin Pressure: The decline in gross margin percentage due to product mix changes may affect profitability metrics.
Cash Flow Timing: Seasonal compensation and timing of revenue collections led to higher cash use in Q1, although improvements are expected in Q2.

5. Notable Q&A Insights

MAC Reimbursement: All seven Medicare Administrative Contractors (MACs) are now reimbursing for RECELL, with one MAC adjusting rates to align with others.
Growth Drivers: Both RECELL and Cohealyx contributed to revenue growth, with a focus on smaller burns driving increased adoption of RECELL.
Sales Strategy: The sales team is adapting to customer preferences for smaller, more frequent orders, enhancing revenue predictability.
Cohealyx Adoption: Positive feedback from surgeons and early repeat usage indicate growing confidence in Cohealyx, with expectations for continued progress in VAC approvals.

Overall, AVITA Medical is showing signs of recovery and growth, with strategic initiatives aimed at stabilizing the business and enhancing product adoption. However, challenges remain regarding market dynamics and cash flow management.

RCEL — AVITA Medical, Inc.